JP2016530890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530890A5 JP2016530890A5 JP2016542356A JP2016542356A JP2016530890A5 JP 2016530890 A5 JP2016530890 A5 JP 2016530890A5 JP 2016542356 A JP2016542356 A JP 2016542356A JP 2016542356 A JP2016542356 A JP 2016542356A JP 2016530890 A5 JP2016530890 A5 JP 2016530890A5
- Authority
- JP
- Japan
- Prior art keywords
- medium
- producing
- cells
- kit
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 15
- 241000700605 Viruses Species 0.000 claims 10
- 239000013612 plasmid Substances 0.000 claims 8
- 102100021696 Syncytin-1 Human genes 0.000 claims 7
- 101710091045 Envelope protein Proteins 0.000 claims 6
- 101710188315 Protein X Proteins 0.000 claims 6
- 230000002378 acidificating effect Effects 0.000 claims 6
- 241000713666 Lentivirus Species 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 101150047047 gag-pol gene Proteins 0.000 claims 1
- 108700004030 rev Genes Proteins 0.000 claims 1
- 101150098213 rev gene Proteins 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1358909 | 2013-09-16 | ||
| FR1358909A FR3010720B1 (fr) | 2013-09-16 | 2013-09-16 | Procede de production de virus enveloppes |
| PCT/FR2014/052279 WO2015036713A1 (fr) | 2013-09-16 | 2014-09-12 | Procede de production de virus enveloppes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530890A JP2016530890A (ja) | 2016-10-06 |
| JP2016530890A5 true JP2016530890A5 (OSRAM) | 2017-10-19 |
| JP6629210B2 JP6629210B2 (ja) | 2020-01-15 |
Family
ID=50424334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542356A Ceased JP6629210B2 (ja) | 2013-09-16 | 2014-09-12 | エンベロープウイルスの産生方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10125352B2 (OSRAM) |
| EP (1) | EP3047025B1 (OSRAM) |
| JP (1) | JP6629210B2 (OSRAM) |
| CN (1) | CN105722984B (OSRAM) |
| CA (1) | CA2923554C (OSRAM) |
| DK (1) | DK3047025T3 (OSRAM) |
| ES (1) | ES2732154T3 (OSRAM) |
| FR (1) | FR3010720B1 (OSRAM) |
| RU (1) | RU2016114541A (OSRAM) |
| SG (1) | SG11201602017YA (OSRAM) |
| WO (1) | WO2015036713A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
| MA45426A (fr) | 2015-10-22 | 2019-05-01 | Juno Therapeutics Gmbh | Procédés, kits, agents et appareils de transduction |
| US12037599B2 (en) | 2019-08-23 | 2024-07-16 | Lonza Walkersville, Inc. | Methods and constructs for production of lentiviral vector |
| IL303847A (en) | 2021-01-28 | 2023-08-01 | Allogene Therapeutics Inc | Methods for transferring immune cells |
| US20250059560A1 (en) * | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007005379A (es) | 2004-11-05 | 2007-07-04 | Wellstat Biologics Corp | Formulaciones de virus envueltos estables y filtrables. |
| EP2007883B1 (en) | 2006-04-20 | 2011-12-28 | Wyeth LLC | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
| EP2307551B1 (en) | 2008-06-18 | 2016-12-14 | Oxford BioMedica (UK) Limited | Purification of retroviral vectors |
| CA2839633C (en) * | 2011-06-30 | 2019-08-20 | Genethon | Peptides with viral infection enhancing properties and their use |
| US20140315294A1 (en) * | 2011-11-24 | 2014-10-23 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
-
2013
- 2013-09-16 FR FR1358909A patent/FR3010720B1/fr not_active Expired - Fee Related
-
2014
- 2014-09-12 EP EP14796166.8A patent/EP3047025B1/fr not_active Revoked
- 2014-09-12 US US15/022,049 patent/US10125352B2/en not_active Expired - Fee Related
- 2014-09-12 ES ES14796166T patent/ES2732154T3/es active Active
- 2014-09-12 DK DK14796166.8T patent/DK3047025T3/da active
- 2014-09-12 CA CA2923554A patent/CA2923554C/fr not_active Expired - Fee Related
- 2014-09-12 RU RU2016114541A patent/RU2016114541A/ru not_active Application Discontinuation
- 2014-09-12 CN CN201480050980.4A patent/CN105722984B/zh not_active Expired - Fee Related
- 2014-09-12 WO PCT/FR2014/052279 patent/WO2015036713A1/fr not_active Ceased
- 2014-09-12 SG SG11201602017YA patent/SG11201602017YA/en unknown
- 2014-09-12 JP JP2016542356A patent/JP6629210B2/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bobadilla et al. | Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein | |
| Munis | Gene therapy applications of non-human lentiviral vectors | |
| Lundstrom | RNA viruses as tools in gene therapy and vaccine development | |
| Negre et al. | Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells | |
| Benskey et al. | Lentivirus production and purification | |
| Ura et al. | Developments in viral vector-based vaccines | |
| Kobayashi et al. | Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus | |
| Gao et al. | The influenza A virus PB2, PA, NP, and M segments play a pivotal role during genome packaging | |
| JP7105875B2 (ja) | レトロウイルスベクター | |
| JP2016530890A5 (OSRAM) | ||
| Ziegler et al. | The lymphocytic choriomeningitis virus matrix protein PPXY late domain drives the production of defective interfering particles | |
| JP2016028035A5 (OSRAM) | ||
| RS56844B1 (sr) | Retrovirusni vektori sa modifikovanim polipurinskim nizom | |
| WO2019228117A1 (zh) | 慢病毒载体及其递送外源rna的方法 | |
| Sinn et al. | Lentiviral vectors pseudotyped with filoviral glycoproteins | |
| Hermann et al. | Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46 | |
| JP6629210B2 (ja) | エンベロープウイルスの産生方法 | |
| King et al. | Technical considerations for the generation of novel pseudotyped viruses | |
| JP2024028802A (ja) | レンチウイルスパッケージングシステム、それにより製造されたレンチウイルス、及び、該レンチウイルスで形質導入された細胞、並びに、それを使用して宿主細胞のレンチウイルスの収率を向上させる方法 | |
| Miskin et al. | A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors | |
| Kuate et al. | Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus‐based lentiviral vectors | |
| JPWO2020059848A1 (ja) | レンチウイルスベクター産生の増強方法 | |
| D’Costa et al. | Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation | |
| Olgun et al. | High-titer production of HIV-based lentiviral vectors in roller bottles for gene and cell therapy | |
| Schüle et al. | Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj |